LMAM
MRNA icon

Legg Mason Asset Management’s Moderna MRNA Stock Holding History

Legg Mason Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$415K Buy
+1,633
New +$477K 0.46% 95

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Legg Mason Asset Management's MRNA Position: Q4 2021 in Review

Legg Mason Asset Management opened a new position in Moderna (MRNA) in Q4 2021: 1,633 shares worth $415K. The stake represents 0.46% of the portfolio and ranks #95 among its holdings.

1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • Legg Mason Asset Management held 1,633 shares of Moderna worth $415K as of Q4 2021.
  • Moderna was a new Legg Mason Asset Management position in Q4 2021.
  • Moderna made up 0.46% of Legg Mason Asset Management's portfolio in Q4 2021, its #95 holding.
  • 1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Legg Mason Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.